Company News

ResVita Bio Receives NIH Grant to Develop Breakthrough Treatment for Severe Atopic Dermatitis

From the press release.

The ResVita team. L-R: Founder & CEO Amin Zargar; Maya Stevens, Senior Research Associate; Alex Jackson, Visiting Scientist; Shyam Sah, Senior Scientist; Andrew Hagen, Principal Scientist; Emilie Rennie, Project Manager.

ResVita Bio, a synthetic biology startup and Bakar Labs tenant, announced that it has been awarded a $250,000 Phase 1 Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Disease (NIAID). This grant will be used to develop RVB-101, a genetically engineered cell therapy for the treatment for severe atopic dermatitis.

Dr. Amin Zargar, PhD, Chief Executive Officer of ResVita Bio, expressed his excitement regarding the recent achievement. “Within a year, we have been honored to receive two innovation grants from the NIH to develop therapies for both Netherton Syndrome, an orphan disease, and severe atopic dermatitis through our topical cell therapy approach,” Dr. Zargar stated. “This is in addition to our Rare Pediatric Disease Designation for Netherton Syndrome from the FDA, setting the stage for the entry of our therapy into the clinic in 2025.”

Veteran biopharmaceutical executive and a member of the company’s Advisory Board Steven Lo commended ResVita Bio’s vision, stating, “Continuous production of therapeutic proteins can be a game-changer in disease treatment, and ResVita Bio has made remarkable progress bringing their platform to the cusp of the clinic.”

About RVB-101

RVB-101 is a new type of treatment for severe atopic dermatitis, consisting of genetically engineered cells within a moisturizer formulation. Topically applied, the cells temporarily colonize the skin and continuously release proteins that rebuild the epidermal barrier and alleviate inflammation.

About ResVita Bio

ResVita Bio launched in June 2022 on a mission to restore and maintain the vitality of the skin through the topical application of cellular therapies. By genetically programming living cells, ResVita Bio aims to repair disrupted skin and alleviate inflammation in various inflammatory skin diseases, including Netherton Syndrome, atopic dermatitis, acne rosacea, and psoriasis. ResVita Bio is a recipient of the Bakar Innovation Fellowship, NIAMS SBIR award, NIAID SBIR award, and the AbbVie Golden Ticket at UC Berkeley’s Bakar Labs. For more information on the company, please visit its website at or follow its LinkedIn page.